Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Does BRV Have a Faster Onset Time and Greater Effect Than LEV in Epilepsy Patients: A Prospective, Randomized, Crossover, Double-blind, Controlled Intravenous Study Using the PPR as a Pharmacodynamic Efficacy Endpoint

Next Previous
X
Search
Trial Profile

Does BRV Have a Faster Onset Time and Greater Effect Than LEV in Epilepsy Patients: A Prospective, Randomized, Crossover, Double-blind, Controlled Intravenous Study Using the PPR as a Pharmacodynamic Efficacy Endpoint

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 21 Jan 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brivaracetam (Primary) ; Levetiracetam (Primary)
  • Indications Reflex epilepsy
  • Focus Therapeutic Use

    • Most Recent Events

    • 08 Dec 2020 Results presented at the 74th Annual Meeting of the American Epilepsy Society
    • 19 Sep 2020 Primary endpoint has been met. (median intrapatient BRV:LEV time ratio i.e. PPR elimination)
    • 19 Sep 2020 Primary endpoint has not been met. (Comparison between Brivaracetam and Levetiracetam of the Time to Peak Effect (Abolition) and Time to 50% Diminution in Photo-Paroxysmal Response in Patients with Photosensitive Epilepsy (1))

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top